(WASHINGTON) – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, and Deputy Editor Nancy Berliner, MD. If you would like a PDF copy of any of the manuscripts highlighted below or would like to request an interview with the author, please email firstname.lastname@example.org.
MYC/BCL2 protein co-expression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program, Hu et al.
The activated B cell-like subtype (ABC subtype) of diffuse large B-cell lymphoma (DLBCL) is a malignant lymphoma associated with poor prognosis and is distinguishable by its unique gene-expression profile. In this week’s issue of Blood, Hu and colleagues detail results from an investigation of 893 newly diagnosed DLBCL patients on a standard form of treatment (R-CHOP therapy) showing that MYC/BCL2 protein co-expression is significantly more common in the ABC subtype of the disease. In addition, investigators demonstrate that MYC/BCL2 co-expression in DLBCL is associated with an aggressive clinical course, which contributes to the overall inferior prognosis of patients with ABC-DLBCL. The finding that dual MYC/BCL2 expression in DLBCL is a highly adverse prognostic feature is critically important to informing therapeutic decisions, and the prognostic significance of MYC and BCL2 protein co-expression will lead to changes in the pathologic work-up of these tumors.
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study, Gouw et al.
This study addresses a central question in the care of patients with bleeding disorders and their complications: the impact of intensity and timing of factor replacement on the subsequent development of alloantibodies against factor VIII. In this manuscript, Gouw and colleagues report prospective data from their analysis of a large international network of bleeding disorder centers and provide important details about the previously reported association of prophylaxis with decreased inhibitor risk. Results from this analysis show that prophylaxis may reduce inhibitor risk only after a number of exposure days and that prophylaxis may reduce inhibitor risk only in patients with low-risk F8 mutations. These results have significant clinical implications that may help justify the resource allocation regarding the use of extremely costly clotting factor concentrates in prophylaxis, a therapy option accompanied with a significant healthcare economic impact.
Neutrophil myeloperoxidase regulates T cell-driven tissue inflammation in mice by inhibiting dendritic cell function, Odobasic et al.
While myeloperoxidase (MPO) is an enzyme vital to the process whereby white blood cells destroy intracellular bacteria, it can cause extracellular tissue damage and its role in adaptive immunity and T cell-mediated diseases is poorly understood. In this issue of Blood, investigators show through an extensive series of experiments that MPO, via its catalytic activity, inhibits the generation of adaptive immunity by suppressing dendritic cell activation, antigen uptake/antigen processing, and migration to lymph nodes and consequently limits pathological tissue inflammation. This finding provides keen insight into how a typical enzyme associated with inflammation, through its enzymatic activity on the level of dendritic cell activation, gives a negative feedback signal to dampen adaptive immunity. Further, it marks a major discovery by demonstrating a previously unrecognized mechanism of neutrophil-dendritic cell interaction at the interface to innate and adaptive immunity.
Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.
ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.
blood® is a registered trademark of the American Society of Hematology.
back to top